- Johnson & Johnson will invest more than $1 billion in a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania.
- The facility is expected to support over 500 biomanufacturing jobs and more than 4,000 construction jobs, and forms part of the company’s previously announced $55 billion U.S. investment plan through early 2029.
Johnson & Johnson has announced a more than $1 billion investment to build a next-generation cell therapy manufacturing facility in Montgomery County, Pennsylvania. The site will expand the company’s U.S. manufacturing capacity as it advances its portfolio and pipeline of medicines for cancer, immune-mediated, and neurological diseases.
The new facility will support more than 500 skilled biomanufacturing jobs once fully operational and create more than 4,000 construction jobs during development. The investment forms part of the company’s previously announced $55 billion U.S. investment in manufacturing, research and development, and technology through early 2029.
“The project continues the company’s long-standing commitment to innovation and domestic manufacturing. By uniting scientific excellence with state-of-the-art manufacturing and strategic investment, and by working collaboratively with our communities, we are delivering for patients and creating significant opportunities for workers and families.”
Joaquin Duato, Chairman and Chief Executive Officer of Johnson & Johnson
The facility will incorporate advanced manufacturing processes and workforce training initiatives designed to support emerging technologies in cell therapy. The announcement builds on Johnson & Johnson’s existing footprint in Pennsylvania, where it operates ten facilities spanning more than 2 million square feet across manufacturing, research, distribution, and office operations.
The investment further strengthens the company’s economic impact in Pennsylvania, which it states totals approximately $10 billion annually. State and federal officials noted that the project reinforces Pennsylvania’s position in life sciences and advanced manufacturing while supporting job creation and innovation in the region.
